Skip to main content
SpringerLink
Log in

Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Introduction: Standard therapy for recurrent or metastatic renal carcinoma includes the biologic response modifiers interferon-alpha (IFN-α) and interleukin-2 (IL-2). The response rate for both agents is modest and toxicity is significant. New agents are needed. Interferon-gamma (IFN-γ) is a type II interferon that demonstrated promising activity in renal carcinoma in early clinical trials. In vitro data suggested synergistic activity when IFN-γ was combined with IFN-α. The Eastern Cooperative Oncology Group conducted a randomized phase II trial to confirm the efficacy of IFN-γ as a single agent and to evaluate the efficacy and toxicity of IFN-γ in combination with IFN-α in the treatment of patients with metastatic or recurrent renal carcinomas.

Materials and Methods: Ninety-five patients with recurrent or metastatic renal carcinoma were entered on trial. Patients were stratified based on risk assessment using the Elson method. Patients were randomly assigned to receive either IFN-γ 0.1 mg/m2 weekly (arm A) or IFN-γ 0.3 mg/m2 iv daily × 5 every 3 wk plus IFN-α 10 MU/m2 daily (arm B). Treatment efficacy was evaluated every 6 weeks.

Results: Toxicity in the arm A was minimal. Significant toxicity was noted in arm B, with four cases of grade 4 neurotoxicity. No responses were seen with IFN-γ alone. Five responses (two CR and three PR) were noted in the combination arm for an overall response rate of 10%. Four of five responders were classified as “good risk.” Median survival for arm A was 7.0 mo vs 10.4 mo for arm B. Risk stratification was significant in arm B.

Conclusion: IFN-γ at this dose and schedule failed to demonstrate activity in metastatic/recurrent renal carcinoma. The combination of IFN-γ and IFN-α demonstrated a response rate similar to IFN-α alone. There was no evidence of synergy between IFN-γ and IFN-α.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics—2003. CA-A Cancer Journal for Clinicians 2003; 53:5–26.

    PubMed  Google Scholar 

  2. Slaton JW, Swanson DA. Radical nephrectomy for localized renal cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds). Comprehensive Textbook of Genitourinary Oncology, Second Edition, Lippincott-Williams and Wilkins: Philadelphia, PA, 2000. pp 166–175.

    Google Scholar 

  3. Nelson JB, Marshall FF. Surgical treatment of locally advanced renal cell cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds). Comprehensive Textbook of Genitourinary Oncology, Second Edition, Lippincott-Williams and Wilkins: Philadelphia, PA, 2000. pp 183–200.

    Google Scholar 

  4. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 2003; 21:1214–1222.

    Article  PubMed  CAS  Google Scholar 

  5. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol 2001; 19:425–431.

    PubMed  CAS  Google Scholar 

  6. Clark J, Atkins MB, Urba W, et al. Adjuvant high dose bolus interleukin-2 (HD IL2) for patients with high-risk renal cell carcinoma—A Cytokine Working Group randomized trial. Proc Am Soc Clin Oncol 2003; 22:164.

    Google Scholar 

  7. Krown SE. Interferon treatment of renal cell carcinoma. Cancer 1987; 59:647–651.

    Article  PubMed  CAS  Google Scholar 

  8. Elson P, Witte R, Trump D. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310–7313.

    PubMed  CAS  Google Scholar 

  9. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological respnse modifiers. J Urol 1995; 154:35–40.

    Article  PubMed  CAS  Google Scholar 

  10. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530–2540.

    PubMed  CAS  Google Scholar 

  11. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated system. J Clin Oncol 2001; 19:1649–1657.

    PubMed  CAS  Google Scholar 

  12. Fossa S, Jones M, Johnson P, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 1995; 76:286–290.

    Article  PubMed  CAS  Google Scholar 

  13. Dutcher JP. Interleukin-2 as a single agent in advanced renal cell carcinoma. In: Renal Cell Carcinoma Immunotherapy and Cellular Biology, Klein EA, Bukowski RM Finke JH (eds). Marcel Dekker Inc, New York, 1993, pp. 195–200.

    Google Scholar 

  14. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998; 338:1272–1278.

    Article  PubMed  CAS  Google Scholar 

  15. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688–696.

    PubMed  CAS  Google Scholar 

  16. Saito T, Berens ME, Welander CE. Direct and indirect effects of human recombinant γ-interferon on tumor cells in a clongenic assay. Cancer Res 1986; 46:1142–1147.

    PubMed  CAS  Google Scholar 

  17. Kirkwood JM, Bryant J, Schiller JH, Oken MM, Borden EC, Whiteside TL. Immunomodulatory function of interferon gamma in patients with metastatic melanoma: Results of a phase II-B trial in subjects with metastatic melanoma, ECOG Study E4987. J Immunotherapy 1997; 20:146–157.

    CAS  Google Scholar 

  18. Ernstoff MS, Gooding W, Nair S, et al. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 1992; 52:851–856.

    PubMed  CAS  Google Scholar 

  19. Aulitzky W, Gastl G, Aulitzky W, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989; 12:1875–1884.

    Google Scholar 

  20. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logisthetis CJ: Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma. J Urol 1994; 152:841–845.

    PubMed  CAS  Google Scholar 

  21. Ernstoff MS, Nair S, Bahnson RR, et al. A phase IA trial of sequential administration of recombinant DNA-produced interferon: Combination recombinant interferon gamma and recombinant interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 1990; 8:1637–1649.

    PubMed  CAS  Google Scholar 

  22. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984; 40:819–825.

    Article  PubMed  CAS  Google Scholar 

  23. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Statistical Assoc 1958; 53:457–481.

    Article  Google Scholar 

  24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163–170.

    PubMed  CAS  Google Scholar 

  25. Weiner LM, Steplewski Z, Koprowski H, Litwin S, Comis RL. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and non-specific cytotoxicity by human peripheral blood monocytes. Cancer Res 1988; 48:1042–1046.

    PubMed  CAS  Google Scholar 

  26. Aulitzky W, Gastl G, Aulitzky WE, et al. Interferon-gamma for the treatment of metastatic renal cancer: Dose-dependent stimulation and downregulation of β2 microglobulin and neopterin responses. Immunobiology 1987; 176:85–95.

    PubMed  CAS  Google Scholar 

  27. Small EJ, Weiss FG, Malik UK, et al. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Amer 1998; 4:162–167.

    CAS  Google Scholar 

  28. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med 1998; 338:1265–1271.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept of Biostatistics, University of Wisconsin Cancer Center, 53792-0001, Madison, Wisconsin

    Jason P. Fine

  2. Lankenau Hospital, Wynnewood, Pennsylvania

    Robert L. Krigel

  3. Division of Oncology, Cancer Center, Vanderbilt University, 37232, Nashville, Tennessee

    Barbara A. Murphy

  4. Toledo Clinic, 43623, Toledo, Ohio

    Paul L. Schaefer

  5. Division of Oncology, Cancer Center, Dartmouth-Hitchcock Medical Center, 03756, Lebanon, New Hampshire

    Marc S. Ernstoff

  6. Division of Oncology, Indiana University, 46202, Indianapolis, Indiana

    Patrick J. Loehrer Sr.

  7. Our Lady of Mercy Cancer Center, 600 East 233rd Street, 10466, Bronx, NY

    Janice P. Dutcher MD

Authors
  1. Janice P. Dutcher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason P. Fine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert L. Krigel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara A. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul L. Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marc S. Ernstoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patrick J. Loehrer Sr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janice P. Dutcher MD.

Additional information

deceased

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dutcher, J.P., Fine, J.P., Krigel, R.L. et al. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 20, 271–281 (2003). https://doi.org/10.1385/MO:20:3:271

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:20:3:271

Key Words

Search

Navigation